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Systemic Lupus Erythematosus (SLE) is an autoimmune disease that targets the vascular system, 
and can result in premature atherosclerotic vascular disease.  The causes of SLE and many of the 
SLE associated problems, such as thrombosis, anitphospholipid syndrome, and atherosclerosis, 
which are significant public health concerns, are thought to be multifactorial, or caused by 
interactions of many environmental and genetic factors.  Several genes have been proposed and 
studied in conjunction with these manifestations.  This study focuses on one of these genes, 
apolipoprotein H (APOH gene, β2-GPI protein).  The effects of several polymorphisms within 
the coding region in the APOH gene have been studied; however, possible effects of the single 
nucleotide polymorphisms (SNPs) within the promoter region have not been characterized.  In 
this study, 6 SNPs in the APOH promoter were genotyped in 381 SLE women and 497 healthy 
women controls.  This study aimed to determine the association of these polymorphisms with the 
occurrence of SLE, with the plasma levels of β2-GPI, and with the presence of antiphospholipid 
antibodies (APA).  It was hypothesized that the genetic variation in the promoter region of the 
APOH gene may affect the risk of SLE and may do so  through an effect on plasma β2-GPI 
levels or through its influence on APA.  Among whites, the risk of SLE was modestly affected 
by the -1219 SNP (p = 0.057).  While in blacks, the -759 SNP (p = 0.022) and the -700 SNP (p = 
0.035) showed association with SLE.  The haplotype pattern in whites was associated with SLE 
risk (p = 0.00015). The -643 SNP showed a modest effect on plasma β2-GPI levels in white SLE 
 iii
cases (p = 0.096) and black controls (p = 0.081).  Significant differences were seen between 
antibody negative and all antibody positive groups in whites for the -1284 SNP (p = 0.02) and 
the -759 SNP (p = 0.046).  These results suggest that genetic variation in the APOH promoter 
may affect SLE risk, β2-GPI levels, and the occurrence of antiphospholipid antibodies.  
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1. BACKGROUND AND SIGNIFICANCE 
 
1.1. Introduction 
 
Systemic lupus erythematosus is an autoimmune disease in which autoantibodies are produced 
against nuclear antigens, cytoplasmic antigens, and blood cell surface antigens.  The binding of 
these autoantibodies to their antigens causes the build up of immune complexes in blood vessel 
walls.  This leads to the manifestations of SLE depending on which organs and cell types are 
involved (Trethewey, 2004).  SLE has an incidence of 1.8-7.6 per 100,000 and a prevalence of 
14.6-50.8 per 100,000 in the United Stated.  All ethnic groups are susceptible to SLE; however, 
the incidence in blacks, 1:250, is greater than in whites, 1:1000.  It does not affect the sexes 
equally with a 1:9 male to female ratio, and 80% of cases occur in women in their child-bearing 
years (Lamont, 2005).   
 
The rates of cardiovascular disease in young women with SLE are very high; women in the 35 to 
44 year old age group have a 50-fold increase in risk of myocardial infarction.  SLE targets the 
vacular system with manifestations such as vasculitis, vasculopathy, vasospasm, 
thromboembolism, and, now that SLE patients are living longer, premature atherosclerotic 
vascular disease (Manzi et al. 1997).   
 
An early event in atherosclerosis is the formation of cholesterol-filled foam cells.  Low density 
lipoproteins (LDL) play an important role in foam cell formation.  High levels of LDL particles 
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 can lead to accumulation and modification of LDL into acetylated LDL and oxidized LDL (ox-
LDL) in the subendothelial space.  These modified LDL particles recruit monocytes which 
become macrophages that take up modified LDL and generate foam cells (Fisher et al. 1972).   
Figure 1 provides a picture of an enlarged view of atherosclerosis.  
 
 
 
 
 
Keller S, Atherosclerosis. MedlinePlus Medical Encyclopedia. Updated 2004. 
Figure 1. Atherosclerosis 
 
 
Apolipoproteins associate with lipoproteins and help make up the lipoprotein particles, high 
density lipoprotein (HDL), low density lipoprotein (LDL), very low density lipoprotein (VLDL) 
and chylomicrons (CM).  This study focuses on one specific apolipoprotein called apolipoprotein 
H, or β2-glycoprotein I (APOH gene; β2-GPI protein).  β2-GPI plays a role in the lipoprotein 
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 metabolic pathway, influences the development of atherosclerosis, and plays a role in the 
development of other aspects of SLE. 
 
1.2. Role of apoH in Antiphospholipid syndrome 
 
Another aspect of SLE that causes problems for many women is Antiphospholipid syndrome 
(APS).  Antiphospholipid syndrome occurs when a specific type of autoantibody, anti-
phospholipid antibodies, are present and cause at least one clinical manifestation.  Clinical 
manifestions often include venous or arterial thrombosis or recurrent pregnancy loss.  APS can 
be isolated, called primary antiphospholipid syndrome (PAPS) or it can be a part of another 
disease, particulary SLE (Hanly 2003).   
 
Antiphospholipid antibodies are seen in about 1-5% of healthy individuals in the population; in 
contrast, about 50% of people with SLE have these antibodies.  Approximately 34-42% of 
people with SLE actually develop APS (Carsons 2004).  The major antiphospholipid antibodies 
that have been tested for are anticardiolipin (aCL) and Lupus anticoagulant (LAC).  LACs are a 
family of antiphospholipid-plasma antibodies that interfere with phospholipids dependent 
coagulation reactions.  aCL antibodies are antiphosipholipid antibodies that bind to negatively 
charged phospholipids; they are named for the representative antigen, cardiolipin, which is used 
in the immunoassay to test for aCLs (Kumar et al. 2002).  It is now known that phospholipids are 
not actually the antigens for most of the antibodies seen in APS.  Most of these antiphospholipid 
antibodies actually recognize the protein β2-GPI (Roubey 2004).  Antibodies that directly 
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 recognize β2-GPI, called anti- β2-GPI antibodies are also tested for when considering APS in 
addition to aCL and LAC. 
 
1.3. Role of β2-GPI in Lipid Metabolism and Atherosclerosis 
 
β2-GPI has been shown to play a role in phospholipid-dependent reactions, cholesterol transport, 
foam cell formation, and ultimately, atherosclerosis.  As mentioned previously, cholesterol 
accumulation in the cells of vessel walls is a characteristic of atherosclerosis.  Data from a study 
by Lin et al (2001) has shown that β2-GPI has some control over cholesterol transport.  It reduced 
the influx of [3H]CE-labeled oxidized LDL (ox-LDL) and slightly increased the efflux of [3H] 
cholesterol.  Therefore, it increased the net efflux of cholesterol.  The same study also suggested 
that β2-GPI may inhibit oxidation of LDL particles.  Oxidized LDL has an increased 
electrophoretic mobility in the presence of copper as compared to native LDL.  When ox-LDL 
particles were treated with β2-GPI the relative electrophoretic mobility (REM) was reduced in a 
dose-dependent manner.  This inhibitory effect was diminished when treatment with anti- β2-GPI 
antibodies was added.  This study has shown that β2-GPI may work to inhibit LDL oxidation and 
may also reduce cholesterol accumulation in macrophages.  Both of these steps are thought to be 
important factors in atherosclerosis; thus, β2-GPI may play a role in prevention of 
atherosclerosis.  Additionally this prevention is compromised in the presence of anti- β2-GPI 
antibodies (Lin et al. 2001).   
 
Hasunuma et al (1997) showed that β2-GPI binds to all oxidized plasma lipoproteins in vitro.  
They found that the binding of β2-GPI to oxidized LDL (ox-LDL) partially inhibited uptake by 
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 macrophages of ox-LDL in vitro.  This effect was dose dependent and was only partial, even at 
the highest β2-GPI level (1200 µg/ml).  About 50% of ox-LDL binding to macrophages was 
inhibited when 400 µg/ml of β2-GPI was used; this is twice the average concentration of this 
protein.  This inhibition of ox-LDL uptake is anti-atherogenic.  However, when aCL or anti- β2-
GPI antibodies were added along with β2-GPI the binding of ox-LDL to macrophages was 
significantly increased, up to 211% and 208% respectively (Hasunuma et al. 1997).  
 
β2-GPI normally binds weakly to membranes with anionic phospholipids, but does not inhibit 
binding of anticoagulant proteins or coagulation factors.  However, the presence of anti- β2-GPI 
antibodies creates crosslinked complexes that bind more tightly to membranes and inhibit the 
binding of other phospholipids binding proteins (Takeya et al. 1997).  This may play a role in 
harmful processes such as thrombosis.  For example, a recent study has shown that 
antiphospholipid antibodies inhibit the binding of annexin V to endothelial cells and trophoblasts 
in the presence of β2-GPI (Rand et al. 1997).  Annexin V is thought to have antithrombotic 
function.  These antibodies are seen more frequently in the SLE population than they are in the 
general population; likewise, thrombosis is also seen more frequently in those with SLE and APS 
then people in the general population.   
 
1.4. Molecular Aspects of ApoH 
 
The APOH gene is 18 kb long with 8 exons and has been mapped to chromosomal location 
17q23-17q24.  It codes for 326 amino acids which make up a single chain glycoprotein with a 
molecular weight of about 50 kDa (Lozier et al. 1984).  Of 8 exons, exons 2 through 7 code for 
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 short consensus repeats (SCRs).  Four SCRs are encoded by 4 separate exons and the fifth SCR 
is encoded by 2 exons.  Exon 1 encodes the 5’ UTR and the single peptide sequences; the 
transcription initiations site is deemed +1 and is located 31 bp upstream from the translational 
start codon.  Exon 8 encodes the 3’UTR, the stop codon, and the C-terminus (Okkels et al. 1999).     
 
This protein is made up of 5 domains, four complement control protein (CCP) modules and a 
fifth domain.  The fifth domain is positively charged and provides a binding region for 
negatively charged substances such as phospholipids (Schwarzenbacher et al. 1999).  Sanghera et 
al (1996) found two structural mutations in the fifth domain of β2-GPI.  Homozygotes for these 
mutations as well as compound heterozygotes lack the ability to bind to negatively charged 
phosphatidylserine (PS), indicating that the fifth domain is the location for the lipid binding 
region.  Wang et al (2001) have provided evidence that β2-GPI binds to the lipid layer in two 
different orientations.  It has an upright orientation in the liquid phase region and a flat 
orientation in the condensed domain region.  The different types of lipoproteins are each partially 
composed of β2-GPI.  It makes up 17% of HDLs, 16% of CMs and VLDLs, and 2% of LDLs 
(Lozier et al. 1984).   
 
ApoH was originally thought to be produced in only the liver.  It has since been shown, using 
reverse transcriptase-polymerase chain reaction (RT-PCR) and southern analysis to analyze 
expression levels, that it is also expressed at the mRNA level in the small and large intestines 
(Averna et al. 1997).  Similarly, Caronti et al (1999) demonstrated that β2-GPI mRNA is 
expressed in many cell types which are involved in anti-phospholipid syndrome (APS) using RT-
PCR.  They observed expression in endothelial cells, which are targeted by autoantibodies in 
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 APS, astrocytes and neurons which are involved in the central nervous system stymptoms of 
APS, and in lymphocytes which are targeted by a large number of antibodies that are seen in 
patients with SLE. 
 
1.5. APOH Promoter Polymorphisms 
 
Several polymorphisms within the coding region of the APOH gene have been found to have 
functional significance.  Mutations at codons 306 and 316 have been shown to inhibit apoH  
binding to cardiolipin (Mehdi et al. 2000).  A specific SNP in the APOH gene at codon 247 has 
been found to interact with another defective allele to increase plasma triglycerides and LDL 
cholesterol in familial hypercholesterolemia families (Takada et al. 2002).  
 
Kamboh et al (2004) have explained the molecular basis for the β2-GPI protein polymorphism by 
examining SNPs in the codong region of the APOH gene.  It had previously been found by 
isoelectric focusing that the APOH gene had a structural polymorphism with 4 alleles. These 
alleles were termed APOH*1, APOH*2 (which is the most common allele), APOH*3 (which has 
been split into 3w and 3B base on reactivity with a monoclonal antibody), and APOH*4 (which 
was only observed in the African American population (Kamboh et al. 1988).  The molecular 
basis of the APOH*1 allele, a missense mutation at codon 88, and the molecular basis of the 
APOH*3w a missense mutation at codon 316, was determined in 1997 (Sanghera et al).  Kamboh 
et al (2004) further characterized this structural polymorphism by explaining the remaining 
alleles.  They examined 5 additional SNPs at codon 122 (T>C), codon 135 (G>A), codon 140 
(A>G), codon 141 (C>A), and a -10 A>C mutation at the intron 4- exon 5 junction.  They found 
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 that all people with the APOH*3B allele carried the codon 122 mutation and the codon 135 
mutation.  The APOH*3W allele was found to have arisen on the APOH*3B allele because it 
contained the codon 122 and 135 mutations plus the additional codon 316 mutation previously 
reported.  Likewise the APOH*4 allele was found to have the codon 122 and 135 mutations plus 
an additional codon 141 mutation also providing evidence that it arose from the APOH*3B allele.  
For these reasons new nomenclature was proposed changing the name of original APOH*3B 
allele to APOH*3 and changing the original APOH*4 allele to  APOH*3B.  Thus, the β2-GPI 
protein polymorphism has been explained by several SNPs within the coding region of the 
APOH gene.  While previous studies of APOH coding polymorphisms have found that these 
SNPs have functional significance, polymorphisms within the promoter region of the APOH 
gene have not been thoroughly studied.   
 
The promoter region is located at the 5’ end of the gene and it plays a crucial role in initiation 
and regulation of transcription.  The importance of the promoter is evident because many 
elements of promoters are conserved in different genes.  Likewise, mutations in promoter 
sequences in several genes interfere with expression of the gene and contribute to genetic 
diseases (Nussbaum et al. 2001).  For example, Hall et al (1997) studied a T>G SNP in the 
promoter region of the lipoprotein lipase gene at position -93.  Individuals with the G allele at 
position -93 had lower triglyceride levels than people who were homozygous for the T allele.  
Also the -93G promoter had higher activity levels than the -93T promoter, 24% higher in a rat 
smooth muscle cell line and 18% higher in a human adrenal cell line (Hall et al. 1997).  Likewise 
a SNP (-629 A>C) in the promoter region of the cholesteryl ester transfer protein (CETP) gene 
was found to have functional significance.  The -629A allele was associated with higher HDL 
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 cholesterol and lower CETP mass.  The -629A promoter also showed 25% lower activity levels 
than the -629C promoter (Dachet et al. 2000).  SNPs in the promoter regions of genes can have 
significant effects related to the gene or protein and can affect the activity of the promoter.   
Because of the importance the promoter region plays in gene transcription and eventually protein 
function, it is valuable to study the polymorphisms within the APOH promoter to help determine 
if have any effect on the function of the gene. 
 
The APOH gene has been sequenced in both white and black subjects by the University of 
Washington-Fred Hutchinson Cancer Research Center group and they reported 146 single 
nucleotide polymorphisms (SNPs).  Of these SNPs, 12 are in the promoter region.  Each SNP 
contains two alleles appearing at different frequencies (Table 1.).  Five of these SNPs are present 
only in the African American population.  This study focuses of six of the seven promoter 
polymorphisms that are present in the Caucasian population.  The seventh polymorphism is and 
insertion polymorphism that was not characterized due to difficulties caused by the surrounding 
sequence.   
 
The -1284 polymorphism is present only in the white population.  It is a C>G SNP with a 
reported minor allele frequency being only .02 in European descendents (.01 in the total 
population).  The -1219 polymorphism is a G>A SNP present in both whites and blacks.  The 
reported minor allele frequency is .02 in blacks, .04 in whites, and .03 overall.  The -1190 G>C 
SNP has a reported minor allele frequency of .43 in blacks, .28 in whites, and .35 in the total 
population.  The -759 polymorphism, also present in both blacks and whites, is an A>G SNP.  
The minor allele frequency that has been reported is .12 in African descendents, .20 in European  
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 descendents, and .16 overall.  The -700 C>A SNP has a minor allele frequency of .11 in blacks, 
.20 in whites, and .15 overall.  The final SNP analyzed in this study is a T>C polymorphism at 
position -643.  It has a reported minor allele frequency of .17 in people of both European and 
African descent (http://pga/gs.washington.edu/data/apoh/). 
 
 
Table 1. Frequency of polymorphisms in the APOH promoter region according to the University of 
Washington website:  http://pga/gs.washington.edu/data/apoh/ 
SNP Allele African 
frequency 
European 
frequency
Allele African 
frequency
European 
frequency 
-1284* G 0.00 0.02 C 1.00 0.98 
-1219* A 0.02 0.04 G 0.98 0.96 
-1190* C 0.43 0.28 G 0.57 0.72 
-1075 A 0.02 0.00 G 0.98 1.00 
-1054 G 0.02 0.00 T 0.98 1.00 
-759* G 0.12 0.20 A 0.88 0.80 
-742 + 0.11 0.20 - 0.89 0.80 
-700* A 0.11 0.20 C 0.89 0.80 
-643* C 0.17 0.17 T 0.83 0.83 
-627 C 0.07 0.00 A 0.93 1.00 
-581 C 0.02 0.00 A 0.98 1.00 
-363 T 0.12 0.00 C 0.88 1.00 
 *The SNPs highlighted in blue are the polymorphisms analyzed in this study. 
 
 
1.6. Specific Aims 
 
The specific aims of the current study are as follows: 
1) To determine the allele frequency and genotype distributions of 6 SNPs in the 
promoter region of APOH in whites and blacks. 
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 Hypothesis: The distribution of APOH SNPs is significantly different between 
whites and blacks. 
2) To determine the association of the polymorphisms in the promoter region 
with the occurrence of SLE. 
Hypothesis: Genetic variation in the APOH gene may affect the risk of SLE. 
3) To determine the association of the SNPs in the promoter region with plasma 
levels of β2-GPI. 
Hypothesis: genetic variation in the APOH gene may affect the risk of SLE by 
affecting plasma levels of β2-GPI. 
4) To determine the association of the SNPs in the promter region with the 
occurrence of antiphospholipid antibodies (aCL, LAC, and anti- β2-GPI). 
Hypothesis: Genetic variation in the APOH gene may affect the risk of SLE 
through its influence on the production of antiphospholipid antibodies. 
 
All these pieces of information will help to characterize whether the SNPs in the promoter region 
may have an impact on the APOH gene or β2-GPI protein function.  This is of public health 
relevance because it is known that β2-GPI plays a role in atherosclerosis, thrombosis, and 
antiphospholipid syndrome, among other diseases.  All of these disorders are of public health 
concern, especially atherosclerosis which is the most common disorder of the arteries leading to 
coronary artery disease (Keller 2004). 
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 MATERIALS AND METHODS 
 
1.7. Study Populations 
 
The population used in this study includes 381 females with SLE ages 20-75 (mean age 43.32 
years), of which 335 are European Americans and 46 are African Americans, and 497 healthy 
control females ages 17-81 (mean age 45.25 years), of which 455 are European Americans and 
42 are African Americans.   
 
The SLE women were recruited through a study of Dr. S. Manzi which was funded by AHA, 
Arthritis Foundation, and National Institute of Health.  The purpose of that study was to measure 
cardiovascular disease and risk factors in women with SLE.  All the women were at least 18 
years old and met the 1982 American College of Rheumatology criteria for definite or probable 
SLE (Tan et al. 1982).  All of the SLE patients participated in the Pittsburgh Lupus Registry. 
The control samples had no history of SLE and were obtained from the Central Blood Bank of 
Pittsburgh.  The samples were from the initial baseline visit.  All participants went through the 
informed consent process and provided written informed consent.  This study was approved by 
the University of Pittsburgh Institutional Review Board. 
 
1.8. DNA Isolation and PCR 
 
Genomic DNA had been isolated from buffy coat using the QIAamp kit (QIAGEN).  For each 
sample, 1 µg of genomic DNA was amplified in a 50 µl reaction mixture composed of 5µl of 
12 
 10X PCR buffer (100mM Tris-HCl, pH=8.3, 500mM KCl), 4µL of  50 mM MgCl₂, 1.25mM of 
each dNTP (Pharmacia), .25 µL of one 20 µmol/L primer, .025 µL of othe other 20 µmol/L 
primer including the universal tag sequence, .25 µL of 20µmol/L biotinylated universal tag 
sequence, and 1.25 units of Taq DNA polymerase (Display Biosystems).  The DNA was 
denatured at a temperature of 95°C for 5 minutes and then the reaction mixture was subjected to 
45 cycles of the following steps: 30 seconds at 95°C (denaturation), 30 seconds at 60°C 
(annealing), and 30 seconds at 72°C (extension).  Finally the mixture underwent a final extension 
step at 72°C for 5 minutes.  For this study, two different PCR fragments were amplified each 
containing 3 SNPs.  For specific primers and conditions see Table 1.  The size and purity of the 
product was determined by gel electrophoresis by running out 5µl of the PCR product on a 2 % 
agarose gel.  
 
 
Table 2 . PCR conditions and primers 
PCR 
Fragment 
 SNPs  PCR conditions  Primers 
       
    95°C for 5 min. - 1 cycle  Biotinylated Universal Tag- 5' GCTGCTCCGG 
  -1284  95°C for 30 sec  TTCATAGATT 
PR.2  -1219  60°C for 30 sec -> 45 cycles  Forward Primer + tag- 5' AGCGCTGCTCCGG 
  -1190  72°C for 30 sec  TTCATAGATTTCTCCCTGACAGATGGAGATT 
    72°C for 5 min. -1 cycle  Reverse Primer- 5' CACACCTGAAGCCTTTCC 
       
    95°C for 5 min. - 1 cycle  Biotinylated Universal Tag- 5' GCTGCTCCGG 
  -759  95°C for 30 sec  TTCATAGATT 
PR.3  -700  60°C for 30 sec -> 45 cycles  Forward Primer- 5' _GAACCCTCTCAAGCAACA 
  -643  72°C for 30 sec  Reverse Primer + tag- 5' AGCGCTGCTCCGG 
    72°C for 5 min. -1 cycle  TTCATAGATTTTGCAAGCTCCTATAGCTCCA 
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 1.9. Genotype Determination 
 
Genotypes were determined using pyrosequencing, a technology that can be used to analyze bi-, 
tri-, and tetra-allelic polymorphisms, multiple SNPs at once, and insertions/deletions.  The 6 
SNPs analyzed in this study were done in 3 duplex assays on the pyrosequencing machine.  See 
Table 2 for sequencing primers and conditions for each assay. 
 
Table 3. Pyrosequencing Assay information   
Pyrosequencing Assays   
-1284 & -1190   
dispensation order  GCTCGCGATCACGCGT 
- 1283 sequencing primer  CTAAAATTCCCTGAGACAC 
-1190 sequencing primer  TTAATGGCTGCCTCC 
-1285 & -759   
dispensation order  GCTCGATAGACTCG 
- 1218 sequencing primer  AGCTCTGAATAAATAACCTC 
-759 sequencing primer  TCAGCACTGGCCC 
-700 & -643   
dispensation order  GCTGAGATACACTCA 
- 700 sequencing primer  CCCAAGTTGTTAATTTCA 
-643 sequencing primer  CTAGACAGATCCAAGACATA 
 
 
 
 
 
Each PCR amplified sample is converted to a single stranded DNA template to which a specific 
sequencing primer is annealed in a single well on a 96 well plate.  The pyrosequencing machine 
first dispenses the enzymes, DNA polymerase, ATP sulfurylase, luciferase, and apyrase and the 
substrates, adenosine 5’ phosphosulfate (APS) and luciferin into each well containing a sample.  
Next the dNTPs are added to the reaction mixture one at a time in a given sequence.  If the dNTP 
that is added is complementary to the template strand, then DNA polymerase incorporates it into 
the DNA strand.  Each time a dNTP is incorporated and equimolar amount of pyrophosphate 
14 
 (PPi) is released and subsequently converted to ATP by ATP sulfurylase and APS.  The ATP and 
luciferase convert luciferin to oxyluciferin, which produces visible light in an amount 
proportional to the amount of ATP and therefore proportional to the number of nucleotides 
incorporated.  The light produced is detected by the charge coupled device (CCD) camera within 
the machine, and is displayed on the computer as a peak with in the pyrogram.  Finally, apyrase 
continuously degrades unused dNTPs and excess ATP.  The peak heights seen are proportional 
to the number of nucleotides incorporated, and if a nucleotide is dispensed that is not 
complimentary to the next nucleotide on the template strand, then no light is produced and no 
peak is seen.  As the complementary strand is formed, the nucleotide sequence is determined by 
the peaks in the pyrogram. 
 
Software that is used with the PSQ-96MA automatically analyzes the data, and the data can also 
be manually analyzed by the user on the computer (Biotage, 2005).  Figures 2, 3, and 4 show 
example pyrograms and theoretical histograms for each genotype of each SNP analyzed. 
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“Principle of pyrosequencing”, www.pyrosequencing.com, Biotage, 2005 
 Figure 2. Diagram of the principle of pyrosequecing 
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Figure 3. Sample pyrograms and theoretical histograms from -1284 & -1190 Pyrosequencing assay 
 
 
17 
 Actual Pyrogram 
c(-1219G>A): C/T   
-759A>G: A/G                                      c( -1219): C/T           -759:A/G 
1240
1260
1280
1300
1320
1340
1360
1380
1400
1420
1440
E S G C T C G A T A G A C T C G
C/T
A/G
 1 
 2 
5 10  
 
Theoretical histogram 
0
2
G C T C G A T A G A C T C G  
Actual Pyrogram 
c(-1219G>A): C/C  
-759A>G: A/A                                        c(-1219):C/C                      -759: A/A 
1220
1240
1260
1280
1300
1320
1340
1360
1380
1400
1420
1440
1460
1480
E S G C T C G A T A G A C T C G
C/C
A/A
 1 
 2 
5 10  
 
Theoretical Histogram 
0
2
G C T C G A T A G A C T C G  
 
Actual program 
c(-1219G>A): T/T  
-759A>G: G/G                                C(-1219):T/T           -759:G/G 
1220
1230
1240
1250
1260
1270
1280
E S G C T C G A T A G A C T C G
T/T
G/G
 1 
 2 
5 10  
 
Theoretical histogram 
0
2
G C T C G A T A G A C T C G  
Figure 4. Sample pyrograms and theoretical histograms from -1219 & -759 Pyrosequencing assay 
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Figure 5. Sample pyrograms and theoretical histograms from -700 & -643 Pyrosequencing assay 
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 1.10. Antiphospholipid antibodies and β2-glycoprotein I quantitation 
 
All patients and controls were previously tested for the presence of antiphospholipid antibodies 
(APA) as described (Sanghera et al. 2004).  Briefly, the presence of three APAs was measured 
including anti-cardiolipin antibodies (ACL; IgG>15 GPL units; IgM>10 MPL units; Incstar, 
Stillwater, MN, USA), lupus anticoagulant (LAC; partial thromboplastin time or Russell’s viper 
venom time with mix), and anti-β₂-glycoprotein I (a β₂GPI; Quantilite, β₂GPI screen, INOVA 
Diagnostics, San Diego, CA, USA).  Each sample was screen in duplicate and any positive IgG 
or IgM for ACL or LAC is considered positive.  β2-glycoprotein I quantitation was also 
previously done as described by Kamboh et al. (1999). 
 
1.11. Statistical Methods 
 
Allele frequencies were calculated by allele counting.  The significance of deviations of the 
observed genotype frequencies from Hardy-Weinberg equilibrium were tested by Χ2 goodness-
of-fit test.   Χ2 analysis was used to determine genotype differences between races and Z-tests 
were used to determine allele frequency differences.  All further testing was carried out 
separately within the white population and within the black population.  Linkage disequilibrium 
was determined for each pair of SNPs using the R statistical program version 2.1.0.  Genotype 
differences between cases and controls were determined using Χ2 analysis, and Z-tests were used 
to determine allele frequency differences between cases and controls.  EH software was utilized 
to determine the frequency of all possible haplotypes.  This program uses the E-M (expectation 
maximization) algorithm to determine maximum likelihood estimates of the haplotype 
20 
 frequencies.  Z-tests were used to compare haplotype frequencies between cases and controls and 
the T5 statistic, 2[ln(L)cases+ln(L)controls-ln(L)total], was used with 63 df and the Χ2 distribution to 
determine the p-value for total haplotype difference between cases and controls.  β2GPI levels 
were analyzed for each SNP by analysis of variance (ANOVA) adjusted for significant variables 
as determined by stepwise linear regression using the R statistical program.  Analysis of antibody 
carriers was done for the following groups: ACL positive, LAC positive, aβ2GPI positive, 
samples positive for any antibody and samples positive for all three antibodies compared to 
samples that were negative for all three antibodies as controls.  This analysis was done using Χ2 
analysis to determine genotype differences and Z-tests to determine allele frequency differences 
within the SLE population, within the control population, and within the total population.     
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 RESULTS 
 
1.12. Distribution of the APOH promoter polymorphisms in Blacks and Whites 
 
The genotype and allele frequency distributions for each APOH SNP were compared between 
black and white subjects (Tables 4-9).  While the distribution of two SNPs, -1284 and -1190, was 
similar between blacks and whites, the other 4 SNPs showed significant difference between the 
two groups.  The genotype distribution for the -1219 SNP was not different between blacks and 
whites (p = 0.247); however, the allele frequencies were significantly different.  The frequency 
of the A allele was 5.6% in blacks and 9.6% in whites (p= .042) (Table 5).  The frequencies of 
the less common alleles at the other 3 polymorphic sites were significantly higher in whites than 
blacks (SNP- 759, 24.8% vs. 12.7%, p < 0.001;  SNP -700, 25.3% vs. 12%, p < 0.001; and SNP -
643, 14.9% vs. 9.1%, p = 0.017).  
 
Table 4. Distribution of the -1284 polymorphism between blacks and whites. 
                
   BLACKS  WHITES 
Genotype  n %  n % 
        
CC  81 98.8  758 99.6 
CG  1 1.2  3 0.4 
GG  0 0  0 0 
       
Total   82     761   
    χ² = 1.07; p= 0.302  
               
   BLACKS  WHITES 
Allele Frequency       
C  0.994  0.998 
G   0.006   0.002 
    p= 0.515   
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Table 5. Distribution of the -1219 polymorphism between blacks and whites. 
               
   BLACKS  WHITES 
Genotype  n %  n % 
        
AA  0 0  11 1.5 
AG  9 11.1  118 16.2 
GG  71 88.9  600 82.3 
       
Total   81     729   
    χ² = 2.80; p= 0.247  
               
   BLACKS  WHITES 
Allele Frequency       
A  0.056  0.096 
G   0.994  0.904 
    p= 0.042   
                
        
 
 
 
Table 6. Distribution of the -1190 polymorphism between blacks and whites. 
               
   BLACKS  WHITES 
Genotype  n %  n % 
        
CC  12 14.5  92 12.2 
CG  39 47.0  375 49.7 
GG  32 38.6  288 38.1 
       
Total   83   755   
    χ² = 0.423; p= 0.809  
               
   BLACKS  WHITES 
Allele Frequency       
C  0.38  0.37 
G   0.62  0.63 
    p= 0.801   
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Table 7. Distribution of the -759 polymorphism between blacks and whites. 
               
   BLACKS  WHITES 
Genotype  n %  n % 
        
AA  60 75.9  404 56.2 
AG  18 22.8  273 38.0 
GG  1 1.3  42 5.8 
       
Total   79   719  
    χ² = 12.05; p= 0.002  
               
   BLACKS  WHITES 
Allele Frequency       
A  .873  .752 
G   .127  .248 
    p= <0.001   
                
        
 
 
 
Table 8. Distribution of the -700 polymorphism between blacks and whites. 
               
   BLACKS  WHITES 
Genotype  n %  n % 
        
AA  1 1.3  46 6.4 
AC  16 21.3  274 37.8 
CC  58 77.3  404 55.8 
       
Total   75   724  
    χ² = 13.47; p= 0.001  
               
   BLACKS  WHITES 
Allele Frequency       
A  0.12  0.253 
C   0.88  0.747 
    p= <0.001   
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 Table 9. Distribution of the -643 polymorphism between blacks and whites. 
               
   BLACKS  WHITES 
Genotype  n %  n % 
        
CC  0 0.0  18 2.4 
TC  15 18.3  185 24.9 
TT  67 81.7  541 72.7 
       
Total   82 744    
    χ² = 4.11; p= 0.128  
               
   BLACKS  WHITES 
Allele Frequency       
C  0.091  0.149 
T   0.909  0.851 
    p= 0.017   
                
 
1.13. Pairwise Linkage Disequalibrium 
 
The pairwise linkage disequilibrium (LD) data for 6 APOH promoter SNPs are presented in 
Table 11 for whites and Table 12 for blacks.  Both D’ and p-values are present to represent the 
extent of LD between SNPs.  Among whites, the -1284 SNP was in significant LD with the 
adjacent two SNPs, -1219 and -1190, but not with the farthest 3 SNPs.  Likewise the -1219 SNP 
was in significant LD with the adjacent 4 SNPs but not with the farthest SNP, -643.   
 
In the black population several SNP pairs seem to be in nearly complete linkage disequilibrium; 
however, this is not statistically significant due to the small sample size and minor allele 
frequency; this includes -643 paired with -1219, -759, and -700 as well as -1190 paired with -
1284.  The -759 SNP is nearly in complete LD the -1284 SNP in blacks (D’ = .985, p = .012); 
25 
 however, the minor allele frequency of the -1284 SNP is very low.  Also, the -759 SNP is in 
close LD with the -700 SNP in the black population (D’ = .933, p <.001). 
 
 
Table 10. Pairwise measure of Linkage Disequalibrium (D') of APOH promoter polymorphisms in whites. 
  -1284 -1219 -1190 -759 -700 -643 
    D' D' D' D' D' 
-1284   0.385 0.945 0.050 0.067 0.767 
-1219 p= 0.048   0.582 0.620 0.635 0.010 
-1190 p= 0.034 p= <.001   0.846 0.926 0.812 
-759 p= 0.961 p= <.001 p= <.001   0.923 0.713 
-700 p= 0.948 p= <.001 p= <.001 p= <.001   0.954 
-643 p= 0.589 p= 0.815 p= <.001 p= <.001 p= <.001  
 
 
 
 
Table 11. Pairwise measure of Linkage Disequalibrium (D') of APOH promoter polymorphisms in blacks. 
  -1284 -1219 -1190 -759 -700 -643 
    D' D' D' D' D' 
-1284  0.763 0.965 0.985 0.890 0.856 
-1219 p= 0.857   0.681 0.352 0.528 0.987 
-1190 p= 0.449 p= 0.008   0.771 0.880 0.766 
-759 p= 0.012 p=0.006 p= <.001   0.933 0.994 
-700 p= 0.757 p= <.001 p= <.001 p= <.001   0.994 
-643 p= 0.789 p= 0.346 p= 0.016 p= 0.134 p= 0.154   
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 1.14. Association of the APOH polymorphisms with SLE 
 
Association studies for SNPs have found that some SNPs alone alter gene function and disease 
risk.  Therefore, association studies were performed with SLE for each SNP individually.  
However, there is increasing evidence that in genes that are very polymorphic, like APOH, 
haplotype structure may be more important in influencing phenotypes rather than individual 
SNPs (McDonald et al. 2002).  Likewise, the linkage disequilibrium studies showed that all the 
SNPs in the APOH promoter are not completely unlinked.  Thus, association between haplotype 
structure and SLE was also performed.  
 
1.14.1. Individual SNP associations with SLE 
 
The association of each SNP with SLE was determined using a case-control model for whites 
and blacks separately.  χ² tests were used to determine genotype differences between cases and 
controls and Z-tests were used to determine allele frequency differences.  This data is displayed 
in Tables 13-19.   
 
The -1284 polymorphism did not show association with SLE.  The minor allele is rare and was 
only seen in 3 white individuals and 1 black individual, 3 cases and 1 control (Table 13).  The     
-1219 polymorphism was not significantly associated with SLE in blacks.  The distribution of 
genotypes (blacks: χ² = 0.659, p = 0.637) and allele frequencies (blacks p = 0.659) were 
comparable between SLE cases and healthy controls in blacks.  In whites, there was not a 
significant difference in genotype frequencies; however, when genotypes AA + AG were 
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 compared to GG there was a borderline significant association with SLE (χ² = 3.61.; p= 0.057).  
There was a slight difference in allele frequencies (p = 0.089).  The frequency of the G allele was 
greater in cases (0.919) than in controls (0.893) (Table 14). 
 
The -1190 SNP was not significantly different between cases and controls in whites or blacks.   
The -759 polymorphism did not show association with SLE risk in whites; however, there was a 
significant association in blacks (Table 16).  The genotype distribution differed between cases 
and controls χ² = 7.61, p = 0.022 and the G allele was more frequent in cases (0.175) than in 
controls (0.077) (p = 0.06).      
 
Similarly, the -700 allele was also associated with SLE risk in blacks, but showed no association 
in whites (Table 17).  The genotype distribution was significantly different between black cases 
and black controls (χ² = 6.72, p = 0.035).  The allele frequency also differed slightly between 
cases and controls (p = 0.098). 
 
The -643 genotype frequency did not significantly differ between cases and controls in whites (χ² 
= 0.75, p = 0.688) or blacks (χ² = 0.36, p = 0.548).  Similarly there was no difference in allele 
frequencies in either whites (p = 0.593) or blacks (p = 0.583) (Table 18). 
 
 
 
 
 
 
28 
  
Table 12. Distribution of the APOH -1284 Polymorphism between cases and controls in blacks and whites. 
          
GENOTYPE  CASES  CONTROLS 
whites  n %  n % 
CC  323 99.4  436 99.8 
CG  2 0.6  1 0.2 
GG  0 0  0 0 
Total  325   437  
        
    χ² = 0.71; p= 0.399  
blacks       
CC  41 97.6  40 100 
CG  1 2.4  0 0 
GG  0 0  0 0 
Total  42   40  
        
    χ² = 0.96; p= 0.326  
Allele Frequency       
whites       
C  0.997  0.999 
G  0.003  0.001 
    p= 0.404   
blacks       
C  0.998  1 
G  0.012  0 
    p= 0.313   
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Table 13. Distribution of the APOH -1219 Polymorphism between cases and controls in blacks and whites. 
 
GENOTYPE  CASES  CONTROLS 
whites  n %  n % 
AA  5 1.6  6 1.4 
AG  40 13  79 18.6 
GG  263 85.4  339 80 
Total  308   424  
        
 χ² = .42; p= 0.123  
 GG vs. AA+AG: χ² = 3.61.; p= 0.057  
      
blacks       
AA  0 0  0 0 
AG  4 9.5  5 12.8 
GG  38 90.5  34 87.2 
Total  42   39  
        
        χ² = 0.22; p=0.637   
Allele Frequency       
whites       
A  0.081  0.107 
G  0.919  0.893 
    p= 0.089   
blacks      
A  0.048  0.064 
G  0.952  0.936 
        p= 0.659     
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Table 14. Distribution of the APOH -1190 Polymorphism between cases and controls in blacks and whites. 
              
GENOTYPE  CASES  CONTROLS 
whites  n %  n % 
CC  40 0.12  52 12 
CG  156 48.3  219 50.5 
GG  127 39.3  163 37.6 
Total  323   434  
        
    χ² = 0.35; p= 0.840  
blacks       
CC  8 18.6  4 10 
CG  20 46.5  19 47.5 
GG  15 34.9  17 42.5 
Total  43   40  
        
        χ² = 1.38; p= 0.502   
Allele 
Frequency       
whites       
C  0.365  0.372 
G  0.635  0.628 
    p= 0.78   
blacks      
C  0.419  0.338 
G  0.581  0.663 
        p= 0.28     
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Table 15. Distribution of the APOH -759 Polymorphism between cases and controls in blacks and whites. 
              
GENOTYPE  CASES  CONTROLS 
whites  n %  n % 
CC  158 54.3  247 57 
CG  116 39.9  158 36.7 
GG  17 5.8  25 5.8 
Total  291   430  
        
    χ² = .75; p= 0.687  
blacks       
CC  26 65  34 87.2 
CG  14 35  4 10.3 
GG  0 0  1 2.6 
Total  40   39  
        
        χ² = 7.61; p= 0.022   
Allele 
Frequency       
whites       
C  0.742  0.758 
G  0.258  0.242 
    p= 0.492   
blacks      
C  0.825  0.923 
G  0.175  0.077 
        p= 0.06     
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Table 16. Distribution of the APOH -700 Polymorphism between cases and controls in blacks and whites. 
              
GENOTYPE  CASES  CONTROLS 
whites  n %  n % 
AA  21 6.9  25 5.9 
AC  117 38.2  159 37.8 
CC  168 54.9  237 56.3 
Total  306   421  
        
    χ² = 0.311; p= 0.856  
blacks       
AA  0 0  1 2.9 
AC  13 31.7  3 8.8 
CC  28 68.3  30 88.2 
Total  41   34  
        
        χ² = 6.72; p= 0.035   
Allele 
Frequency       
whites       
A  0.26  0.248 
C  0.74  0.752 
    p= 0.864   
blacks      
A  0.159  0.074 
C  0.841  0.926 
        p= 0.098     
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Table 17. Distribution of the APOH -643 Polymorphism between cases and controls in blacks and whites. 
              
GENOTYPE  CASES  CONTROLS 
whites  n %  n % 
CC  7 2.2  11 2.6 
CG  83 26.3  102 23.7 
GG  225 71.4  318 73.8 
Total  315   431  
        
    χ² = 0.75; p= 0.688  
blacks       
CC  0 0  0 0 
CG  7 15.9  8 21 
GG  37 84.1  30 78.9 
Total  44   38  
        
        χ² = 0.36; p= 0.548   
Allele 
Frequency       
whites       
C  0.154  0.144 
G  0.846  0.856 
    p= 0.593   
blacks      
C  0.08  0.105 
G  0.92  0.895 
        p= 0.583     
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 1.14.2. Haplotype associations with SLE 
 
Six-site haplotype analysis was performed to determine their association with SLE risk in the 
white case-control sample.  The haplotype frequencies were determined in both SLE cases and 
healthy controls.  Z tests were performed to identify associations of haplotypes with SLE risk.   
26 different haplotypes were present in the white subjects.  Eight of these haplotypes were 
significantly different between cases and controls (highlighted in Table 18).  Six haplotypes were 
significantly more frequent in cases than controls, indicating that they are associated with a 
greater risk of SLE.   Conversely, 2 haplotypes were significantly more frequent in controls than 
cases, indicating that they may be protective.  There are 4 common haplotypes that are present in 
greater than 10% of the population.  There was no significant difference in the frequencies of 
these haplotypes between cases and controls; therefore these haplotypes do not seem to be 
associated with the risk of SLE.   
 
The T5 test statistic was calculated to determine whether there was an overall difference in 
haplotypes seen in cases and controls.  This difference was detected and was significant (p = 
.00015). 
 
1.15. Association of the APOH polymorphisms with plasma β2-GPI levels 
  
Associations of each of promoter SNPS with plasma levels of β2-GPI were carried out using 
analysis of varience (ANOVA) in both whites and blacks.  Linear regression was used to 
determine which covariates significantly affect β2-GPI levels.  BMI (p = .07) and smoking (p =  
35 
 Table 18. Six-site haplotype distribution of APOH promoter polymorphisms in white cases and controls. 
                    
      Haplotype distribution  Total Cases Controls  
          
-
1284 
-
1219 
-
1190 
-
759 
-
700 
-
643 n=641 n=259 n=382 p' 
          
C A C G A C 0.002 0.003 <.001 0.230 
C G C G A C <.001 <.001 0.000 0.899 
C A G G A C 0.001 0.004 0.000 0.174 
C G G G A C <.001 0.002 0.000 0.300 
C A C A C C 0.001 0.000 0.002 0.181 
C G C A C C 0.006 0.010 0.003 0.121 
C A G A C C 0.005 0.005 0.004 0.783 
C G G A C C 0.131 0.127 0.135 0.679 
C G C G C C 0.001 0.002 0.000 0.299 
C A G G C C <.001 0.001 0.000 0.592 
C G G G C C 0.006 0.017 0.000 0.003 
C A C A A T 0.001 0.001 0.000 0.457 
C G C A A T 0.014 0.034 0.001 <.001 
C A C G A T 0.061 0.032 0.081 <.001 
C G C G A T 0.158 0.146 0.165 0.343 
G G C G A T 0.001 0.002 0.000 0.317 
C A G G A T 0.003 0.003 0.003 0.931 
C G G G A T 0.005 0.010 <.001 0.026 
C A C A C T 0.005 0.000 0.010 0.006 
G A C A C T 0.001 0.000 0.001 0.317 
C G C A C T 0.111 0.109 0.111 0.880 
C A G A C T 0.005 0.013 0.000 0.009 
C G G A C T 0.471 0.453 0.482 0.299 
C G C G C T 0.004 0.009 0.000 0.027 
C A G G C T 0.001 0.003 0.000 0.229 
C G G G C T 0.007 0.017 0.000 0.003 
          
                Association studies      
  ln(L)    -1783.160 -783.960 -943.270  
    χ²       1399.620 399.530 1102.850 p=0.00015 ** 
p':p values were calculated using Z-tests to compare haplotype frequencies 
between cases and controls. 
** Calculated from the T5 statistic: 2[ln(L)cases+ ln(L)controls- ln(L)total] 
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 .02) both impacted β2-GPI levels; therefore, they were included as covariates in the ANOVA.  
No significant association was found between β2-GPI levels and the genotypes at the -1284, -
1219, -1190, -759, or -700 positions (Tables 19-23).  The distribution of β2-GPI levels within 
white cases was slightly associated with the genotypes at position -643 (p = .096).  Mean β2-GPI 
levels were 21.07 +/- 1.54 within the CC genotype, 18.25 +/- 3.19 within the TC genotype and 
17.61 +/- 4.00 within the TT genotype.    Similarly, the β2-GPI levels also differed among the 
genotypes for the -643 polymorphism within black controls.  The CC genotype was not present 
in the black subjects studies; the mean β2-GPI level was 19.47 +/- 3.54 for the TC genotype and 
17.67 +/- 2.07 for the TT genotype (Table 24). 
 
 
 
 
Table 19. Distribution of mean plasma β2-GPI levels (+/- SD) among the APOH -1284 polymorphism in blacks 
and whites - adjusted for BMI and smoking. 
  APOH: Genotype  
Whites CC CG GG 
P-Value 
N = 175 N =1  N =0  Controls 
 18.21 +/- 4.62  23.55   
.2186 
N = 231 N =2  N = 0 SLE Cases 
  17.80 +/- 4.11 16.37 +/- 8.76    
 .62057 
          
Blacks  CC CG GG   
N = 21 N = 0 N = 0 Controls 
 18.25 +/- 2.73     
  
N = 28 N = 0 N = 0 SLE Cases 
 18.43 +/- 4.03     
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Table 20. Distribution of plasma β2-GPI levels among the APOH -1219 polymorphism in blacks and whites - 
adjusted for BMI and smoking. 
  APOH: Genotype  
Whites AA AG GG 
P-Value 
N = 1 N = 48 N = 122 Controls 
 23.06  19.19 +/- 4.17  17.98 +/- 4.73 
.1959 
N = 1 N = 26 N = 198 SLE Cases 
 20.48  17.51 +/- 4.22  17.81 +/- 3.98 
 .7808 
          
Blacks  AA AG GG   
N = 0 N = 4 N =  17 Controls 
   18.52 +/- 3.48  18.21 +/- 2.59 
 .7045 
N = 0 N = 1 N = 26 SLE Cases 
   18.56  17.85 +/- 3.00 
 .9315 
          
 
 
 
 
Table 21. Distribution of plasma β2-GPI levels among the APOH -1190 polymorphism in blacks and whites - 
adjusted for BMI and smoking. 
  APOH: Genotype  
Whites CC CG GG 
P-Value 
N = 23 N = 103 N = 47 Controls 
 18.21 +/- 4.45  18.01 +/- 4.91  18.69 +/- 4.26 
 0.6973 
N = 31 N = 112 N = 86 SLE Cases 
 18.32 +/- 2.99  17.62 +/- 4.19  17.69 +/- 4.42 
 0.69887 
          
Blacks  CC CG GG   
N = 1 N = 12 N = 8 Controls 
 13.35  18.35 +/- 2.42  18.68 +/- 2.88 
 0.1387 
N = 6 N = 11 N = 11 SLE Cases 
 18.65 +/- 2.73  17.68 +/- 3.35  19.01 +/- 5.29 
 0.6593 
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Table 22. Distribution of plasma β2-GPI levels among the APOH -759 polymorphism in blacks and whites - 
adjusted for BMI and smoking. 
  APOH: Genotype  
Whites AA AG GG 
P-Value 
N = 93 N =69  N = 12 Controls 
 18.15 +/- 5.02  18.41 +/- 4.27  18.32 +/- 3.19 
 0.9485 
N = 113 N = 84 N = 15 SLE Cases 
 17.75 +/- 3.95  17.81 +/- 3.76  19.10 +/- 2.69 
 0.4210 
          
Blacks  AA AG GG   
N = 17 N = 3 N = 0 Controls 
 18.23 +/- 2.53  16.89 +/- 0.95   
 0.2836 
N = 18 N = 7 N = 0 SLE Cases 
 17.86 +/- 3.32  18.04 +/- 2.35   
 0.7914 
          
 
 
 
Table 23. Distribution of plasma β2-GPI levels among the APOH -700 polymorphism in blacks and whites - 
adjusted for BMI and smoking. 
  APOH: Genotype  
Whites AA AC CC 
P-Value 
N = 12 N = 70 N = 92 Controls 
 18.35 +/- 3.21  18.42 +/- 4.25  18.18 +/- 5.03 
 .9589 
N = 17 N = 81 N = 127 SLE Cases 
 19.01 +/- 2.32  18.29 +/- 3.61  17.51 +/- 3.89 
 .1355 
          
Blacks  AA AC CC   
N = 0 N = 3 N = 17 Controls 
   16.85 +/- 0.95  18.25 +/- 2.56 
 .2836 
N = 0 N = 6 N = 21 SLE Cases 
   18.41 +/- 2.24  18.37 +/- 4.57 
 .8108 
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Table 24. Distribution of plasma β2-GPI levels among the APOH -643 polymorphism in blacks and whites - 
adjusted for BMI and smoking. 
  APOH: Genotype  
Whites CC CT TT 
P-Value 
N = 3 N = 34 N = 137 Controls 
 19.03 +/- 1.14  18.43 +/- 5.18  18.23 +/- 4.51 
 .9300 
N = 5 N = 56 N = 166 SLE Cases 
 21.07 +/- 1.54  18.25 +/- 3.19  17.61 +/- 4.00 
 .09557 
          
Blacks  CC CT TT   
N = 0 N = 4 N = 16 Controls 
   19.47 +/- 3.54  17.67 +/- 2.07 
 .08087 
N = 0 N = 6 N = 22 SLE Cases 
   20.38 +/- 7.14  17.85 +/- 2.74 
 .2198 
          
 
 
 
1.16. Association of the APOH polymorphisms with anti-phospholipid antibodies  
 
Each of the 6 APOH promoter SNPs examined in this study were analyzed for association with 
antiphospholipid antibodies (APA) in whites.  Subjects included in this analysis were screen for 
the presence of 3 different antibodies, anticardiolipin antibodies (aCL), anti-beta2 glycoprotein I 
(β2GPI), and lupus anticoagulant (LAC).  Subjects who were negative for all three antibodies 
were used as the control group.  APA positive groups included positive for all three antibodies 
(ALL 3), positive for at least one antibody (ANY), positive for aCL, positive for β2GPI, and 
positive for LAC.  Each of these five groups were compared to the control group to look for 
differences in genotype distribution.  This was done overall, within SLE cases, and within 
healthy controls for each of the 6 SNPs studied.     
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 For the -1284 SNP a significant difference was found in the genotype distributions between the 
group positive for all 3 antibodies and the antibody negative group overall (p = 0.05) and within 
the SLE cases (p = 0.02).  However, no differences were seen between the allele frequencies of 
these groups.  No significant differences were seen within the control group between the 
antibody negative group and any of the other groups (Tables 25 – 27).  
 
There were no significant associations of antibody status with the -1219 genotypes or allele 
frequencies seen in cases or controls for any of the antibody groups (Tables 28-30).  Similarly, 
there were no differences in allele frequency or genotype distribution for the -1190 SNP between 
any of the antibody groups (Tables 31 -33).   
 
No significant differences were seen between the genotype distributions of the antibody groups 
for the -759 SNP.  However, within the total white population, the allele frequency of the group 
positive for all 3 antibodies (G allele- 0.141) differed from that of the antibody negative group 
(G allele- 0.243) (p = 0.030).  Likewise a difference was seen between the same allele 
frequencies within the SLE cases (p = 0.046).  No other significant differences were seen within 
the controls or in the remaining comparisons in the SLE cases (Tables 34 – 36).   
 
In the total population there was one difference seen in allele frequencies for the -700 SNP.  The 
allele frequency differed slightly (p = 0.095) between the group positive for all 3 antibodies (A 
allele- 0.156) and the group negative for all antibodies (A allele- 0.237).  There were no 
significant differences seen among the genotype distributions in any of the anitbody groups in 
cases or controls (Tables 37 – 39). 
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Finally, no significant differences were found among the antibody groups in genotype 
distributions or allele frequencies of the -643 polymorphism (Tables 40 – 42). 
 
 
 
 
Table 25. Distribution of the -1284 Polymorphism in antibody positive and antibody negative groups in all 
whites. 
               
 ANTIBODY POSITIVE  ANTIBODY NEGATIVE   
 GENOTYPE    GENOTYPE     
ANTIBODY  CC CG GG Total  CC CG GG Total  χ2  p 
aCL  201 1 0 202  314 1 0 315  0.10  0.751 
LAC  134 1 0 135  314 1 0 315  0.38  0.536 
β₂GPI  174 2 0 176  314 1 0 315  1.25  0.264 
ALL 3  32 1 0 33  314 1 0 315  3.85  0.050 
ANY  365 2 0 367   314 1 0 315   0.20   0.654 
               
 ANTIBODY POSITIVE  ANTIBODY NEGATIVE   
 ALLELE FREQUENCY  ALLELE FREQUENCY   
ANTIBODY  C G  C G  Z  p 
aCL  0.998 0.002  0.998 0.002  0.00  1.000 
LAC  0.996 0.004  0.998 0.002  -0.47  0.637 
β₂GPI  0.994 0.006  0.998 0.002  -0.89  0.372 
ALL 3  0.985 0.015  0.998 0.002  -0.86  0.388 
ANY   0.997 0.003   0.998 0.002   -0.37   0.710 
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Table 26. Distribution of the -1284 Polymorphism in antibody positive and antibody negative groups in white 
SLE cases. 
 ANTIBODY POSITIVE  ANTIBODY NEGATIVE   
 GENOTYPE    GENOTYPE     
ANTIBODY  CC CG GG Total  CC CG GG Total  χ2  p 
aCL  80 1 0 81  139 0 0 139  1.72  0.189 
LAC  79 1 0 80  139 0 0 139  1.75  0.186 
β₂GPI  99 2 0 101  139 0 0 139  2.78  0.096 
ALL 3  25 1 0 26  139 0 0 139  5.38  0.020 
ANY  164 2 0 166   139 0 0 139   1.69   0.194 
               
 ANTIBODY POSITIVE  ANTIBODY NEGATIVE   
 ALLELE FREQUENCY  ALLELE FREQUENCY   
ANTIBODY  C G  C G  Z  p 
aCL  0.994 0.006  1 0  -0.99  0.323 
LAC  0.994 0.006  1 0  -0.98  0.326 
β₂GPI  0.99 0.01  1 0  -1.43  0.153 
ALL 3  0.981 0.019  1 0  -1.00  0.316 
ANY   0.994 0.006   1 0   -1.42   0.157 
 
 
Table 27.  Distribution of the -1284 Polymorphism in antibody positive and antibody negative groups in white 
healthy controls. 
 ANTIBODY POSITIVE  ANTIBODY NEGATIVE   
 GENOTYPE    GENOTYPE     
ANTIBODY  CC CG GG Total  CC CG GG Total  χ2  p 
aCL  175 0 0 175  175 1 0 176  1.00  0.318 
LAC  28 0 0 28  175 1 0 176  0.16  0.689 
β₂GPI  40 0 0 40  175 1 0 176  0.23  0.633 
ALL 3  7 0 0 7  175 1 0 176  0.04  0.841 
ANY  201 0 0 201   175 1 0 176   1.15   0.285 
               
 ANTIBODY POSITIVE  ANTIBODY NEGATIVE   
 ALLELE FREQUENCY  ALLELE FREQUENCY   
ANTIBODY  C G  C G  Z  p 
aCL  1 0  0.997 0.003  1.03  0.303 
LAC  1 0  0.997 0.003  1.03  0.303 
β₂GPI  1 0  0.997 0.003  1.03  0.303 
ALL 3  1 0  0.997 0.003  1.03  0.303 
ANY   1 0   0.997 0.003   1.03   0.303 
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Table 28. Distribution of the -1219 Polymorphism in antibody positive and antibody negative groups in all 
white samples. 
 ANTIBODY POSITIVE  ANTIBODY NEGATIVE   
 GENOTYPE    GENOTYPE     
ANTIBODY AA AG GG Total  AA AG GG Total  χ2  p 
aCL  2 24 169 195  2 50 252 304  1.77  0.412 
LAC  1 22 107 130  2 50 252 304  0.03  0.984 
β₂GPI  1 23 151 175  2 50 252 304  0.96  0.619 
ALL 3  0 4 30 34  2 50 252 304  0.75  0.688 
ANY  4 51 299 354   2 50 252 304   0.89   0.640 
               
 ANTIBODY POSITIVE  ANTIBODY NEGATIVE   
 ALLELE FREQUENCY  ALLELE FREQUENCY   
ANTIBODY  A G  A G  Z  p 
aCL  0.072 0.928  0.089 0.911  -0.97  0.330 
LAC  0.092 0.908  0.089 0.911  0.14  0.888 
 0.071 0.929  0.089 0.911  -1.00  0.316 β₂GPI 
ALL 3  0.059 0.941  0.089 0.911  -0.97  0.330 
ANY   0.083 0.917   0.089 0.911   -0.39   0.699 
 
 
 
Table 29. Distribution of the -1219 Polymorphism in antibody positive and antibody negative groups in white 
SLE cases. 
 ANTIBODY POSITIVE  ANTIBODY NEGATIVE   
 GENOTYPE    GENOTYPE     
ANTIBODY AA AG GG Total  AA AG GG Total  χ2  p 
aCL  1 7 73 81  0 20 113 133  3.43  0.180 
LAC  1 8 69 78  0 20 113 133  2.62  0.270 
β₂GPI  0 10 89 99  0 20 113 133     
ALL 3  0 3 24 27  0 20 113 133     
ANY  2 15 143 160   0 20 113 133   3.77   0.152 
               
 ANTIBODY POSITIVE  ANTIBODY NEGATIVE   
 ALLELE FREQUENCY  ALLELE FREQUENCY   
ANTIBODY  A G  A G  Z  p 
aCL  0.056 0.944  0.075 0.925  -0.78  0.433 
LAC  0.064 0.936  0.075 0.925  -0.43  0.665 
β₂GPI  0.051 0.949  0.075 0.925  -1.07  0.286 
ALL 3  0.056 0.944  0.075 0.925  -0.54  0.589 
ANY   0.059 0.941   0.075 0.925   -0.77   0.443 
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Table 30. Distribution of the -1219 Polymorphism in antibody positive and antibody negative groups in white 
healthy controls. 
 ANTIBODY POSITIVE  ANTIBODY NEGATIVE   
 GENOTYPE    GENOTYPE     
ANTIBODY  AA AG GG Total  AA AG GG Total  χ2  p 
aCL  1 17 96 114  2 30 139 171  0.41  0.813 
LAC  0 14 38 52  2 30 139 171  2.72  0.256 
β₂GPI  1 13 62 76  2 30 139 171  0.02  0.992 
ALL 3  0 1 6 7  2 30 139 171  0.14  0.933 
ANY  2 36 156 194   2 30 139 171   0.08   0.963 
               
 ANTIBODY POSITIVE  ANTIBODY NEGATIVE   
 ALLELE FREQUENCY  ALLELE FREQUENCY   
ANTIBODY  A G  A G  Z  p 
aCL  0.083 0.917  0.099 0.901  -0.66  0.512 
LAC  0.135 0.865  0.099 0.901  0.97  0.333 
β₂GPI  0.099 0.901  0.099 0.901  0.00  1.000 
ALL 3  0.071 0.929  0.099 0.901  -0.40  0.691 
ANY   0.103 0.897   0.099 0.901   0.18   0.858 
 
 
 
Table 31. Distribution of the -1190 Polymorphism in antibody positive and antibody negative groups in all 
white samples. 
 ANTIBODY POSITIVE  ANTIBODY NEGATIVE   
 GENOTYPE    GENOTYPE     
ANTIBODY  CC CG GG Total  CC CG GG Total  χ2  p 
aCL  24 90 85 199  33 160 119 312  1.79  0.409 
LAC  15 69 49 133  33 160 119 312  0.09  0.956 
β₂GPI  16 84 74 174  33 160 119 312  0.95  0.621 
ALL 3  2 14 17 33  33 160 119 312  2.42  0.298 
ANY  44 178 140 362   33 160 119 312   0.53   0.769 
               
 ANTIBODY POSITIVE  ANTIBODY NEGATIVE   
 ALLELE FREQUENCY  ALLELE FREQUENCY   
ANTIBODY  C G  C G  Z  p 
aCL  0.347 0.653  0.362 0.638  -0.49  0.625 
LAC  0.372 0.628  0.362 0.638  0.28  0.777 
β₂GPI  0.333 0.667  0.362 0.638  -0.91  0.361 
ALL 3  0.273 0.727  0.362 0.638  -1.53  0.126 
ANY   0.367 0.633   0.362 0.638   0.19   0.849 
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Table 32. Distribution of the -1190 Polymorphism in antibody positive and antibody negative groups in white 
SLE cases. 
 ANTIBODY POSITIVE  ANTIBODY NEGATIVE   
 GENOTYPE    GENOTYPE     
ANTIBODY  CC CG GG Total  CC CG GG Total  χ2  p 
aCL  12 36 30 78  14 67 57 138  1.30  0.523 
LAC  10 34 35 79  14 67 57 138  0.72  0.697 
β₂GPI  13 43 44 100  14 67 57 138  0.90  0.637 
ALL 3  2 11 13 26  14 67 57 138  0.70  0.704 
ANY  25 75 63 163   14 67 57 138   1.79   0.409 
               
 ANTIBODY POSITIVE  ANTIBODY NEGATIVE   
 ALLELE FREQUENCY  ALLELE FREQUENCY   
ANTIBODY  C G  C G  Z  p 
aCL  0.385 0.615  0.344 0.656  0.85  0.396 
LAC  0.342 0.658  0.344 0.656  -0.04  0.966 
β₂GPI  0.345 0.655  0.344 0.656  0.02  0.982 
ALL 3  0.288 0.712  0.344 0.656  -0.81  0.417 
ANY   0.383 0.617   0.344 0.656   0.99   0.321 
 
 
 
Table 33. Distribution of the -1190 Polymorphism in antibody positive and antibody negative groups in white 
healthy controls. 
 ANTIBODY POSITIVE  ANTIBODY NEGATIVE   
 GENOTYPE    GENOTYPE     
ANTIBODY  CC CG GG Total  CC CG GG Total  χ2  p 
aCL  12 54 55 121  19 93 62 174  2.92  0.232 
LAC  5 35 14 54  19 93 62 174  2.22  0.329 
β₂GPI  3 41 30 74  19 93 62 174  3.13  0.209 
ALL 3  0 3 4 7  19 93 62 174  1.76  0.415 
ANY  19 103 77 199   19 93 62 174   0.46   0.796 
               
 ANTIBODY POSITIVE  ANTIBODY NEGATIVE   
 ALLELE FREQUENCY  ALLELE FREQUENCY   
ANTIBODY  C G  C G  Z  p 
aCL  0.322 0.678  0.376 0.624  -1.36  0.174 
LAC  0.417 0.583  0.376 0.624  0.76  0.448 
β₂GPI  0.318 0.682  0.376 0.624  -1.25  0.210 
ALL 3  0.214 0.786  0.376 0.624  -1.44  0.150 
ANY   0.354 0.646   0.376 0.624   -0.62   0.534 
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Table 34. Distribution of the -759 Polymorphism in antibody positive and antibody negative groups in all 
white samples. 
 ANTIBODY POSITIVE  ANTIBODY NEGATIVE   
 GENOTYPE    GENOTYPE     
ANTIBODY  AA AG GG Total  AA AG GG Total  χ2  p 
aCL  121 65 8 194  174 111 18 303  1.56  0.458 
LAC  68 51 7 126  174 111 18 303  0.56  0.756 
β₂GPI  104 58 5 167  174 111 18 303  2.45  0.294 
ALL 3  24 7 1 32  174 111 18 303  3.71  0.157 
ANY  199 132 17 348   174 111 18 303   0.41   0.815 
               
 ANTIBODY POSITIVE  ANTIBODY NEGATIVE   
 ALLELE FREQUENCY  ALLELE FREQUENCY   
ANTIBODY  A G  A G  Z  p 
aCL  0.791 0.209  0.757 0.243  1.26  0.208 
LAC  0.742 0.258  0.757 0.243  -0.46  0.645 
β₂GPI  0.796 0.204  0.757 0.243  1.39  0.165 
ALL 3  0.859 0.141  0.757 0.243  2.18  0.030 
ANY   0.761 0.239   0.757 0.243   0.17   0.866 
 
 
 
Table 35. Distribution of the -759 Polymorphism in antibody positive and antibody negative groups in white 
SLE cases. 
 ANTIBODY POSITIVE  ANTIBODY NEGATIVE   
 GENOTYPE    GENOTYPE     
ANTIBODY  AA AG GG Total  AA AG GG Total  χ2  p 
aCL  42 28 4 74  71 48 8 127  0.07  0.966 
LAC  44 23 5 72  71 48 8 127  0.69  0.710 
β₂GPI  54 36 3 93  71 48 8 127  1.07  0.586 
ALL 3  19 5 1 25  71 48 8 127  3.51  0.173 
ANY  79 61 9 149   71 48 8 127   0.28   0.868 
               
 ANTIBODY POSITIVE  ANTIBODY NEGATIVE   
 ALLELE FREQUENCY  ALLELE FREQUENCY   
ANTIBODY  A G  A G  Z  p 
aCL  0.757 0.243  0.748 0.252  0.20  0.840 
LAC  0.771 0.229  0.748 0.252  0.52  0.604 
β₂GPI  0.774 0.226  0.748 0.252  0.63  0.526 
ALL 3  0.86 0.14  0.748 0.252  2.00  0.046 
ANY   0.735 0.265   0.748 0.252   -0.35   0.728 
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Table 36. Distribution of the -759 Polymorphism in antibody positive and antibody negative groups in white 
healthy controls. 
 ANTIBODY POSITIVE  ANTIBODY NEGATIVE   
 GENOTYPE    GENOTYPE     
ANTIBODY  AA AG GG Total  AA AG GG Total  χ2  p 
aCL  79 37 4 120  103 63 10 176  1.97  0.373 
LAC  24 28 2 54  103 63 10 176  4.49  0.106 
β₂GPI  50 22 2 74  103 63 10 176  2.22  0.329 
ALL 3  5 2 0 7  103 63 10 176  0.69  0.709 
ANY  120 71 8 199   103 63 10 176   0.59   0.746 
               
 ANTIBODY POSITIVE  ANTIBODY NEGATIVE   
 ALLELE FREQUENCY  ALLELE FREQUENCY   
ANTIBODY  A G  A G  Z  p 
aCL  0.813 0.188  0.764 0.236  1.42  0.157 
LAC  0.704 0.296  0.764 0.236  -1.21  0.225 
β₂GPI  0.824 0.176  0.764 0.236  1.55  0.120 
ALL 3  0.857 0.143  0.764 0.236  0.97  0.334 
ANY   0.781 0.219   0.764 0.236   0.55   0.580 
 
 
 
Table 37. Distribution of the -700 Polymorphism in antibody positive and antibody negative groups in all 
white samples. 
 ANTIBODY POSITIVE  ANTIBODY NEGATIVE   
 GENOTYPE    GENOTYPE     
ANTIBODY  AA CA CC Total  AA CA CC Total  χ2  p 
aCL  12 66 113 191  17 113 180 310  0.27  0.872 
LAC  8 54 69 131  17 113 180 310  1.09  0.580 
β₂GPI  7 52 109 168  17 113 180 310  2.17  0.338 
ALL 3  1 8 23 32  17 113 180 310  2.31  0.314 
ANY  22 128 197 347   17 113 180 310   2.80   0.246 
               
 ANTIBODY POSITIVE  ANTIBODY NEGATIVE   
 ALLELE FREQUENCY  ALLELE FREQUENCY   
ANTIBODY  A C  A C  Z  p 
aCL  0.236 0.764  0.237 0.763  -0.04  0.971 
LAC  0.267 0.733  0.237 0.763  0.93  0.352 
β₂GPI  0.196 0.804  0.237 0.763  -1.49  0.137 
ALL 3  0.156 0.844  0.237 0.763  -1.67  0.095 
ANY   0.248 0.752   0.237 0.763   0.46   0.642 
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Table 38. Distribution of the -700 Polymorphism in antibody positive and antibody negative groups in white 
SLE cases. 
 ANTIBODY POSITIVE  ANTIBODY NEGATIVE   
 GENOTYPE    GENOTYPE     
ANTIBODY  AA CA CC Total  AA CA CC Total  χ2  p 
aCL  8 28 41 77  7 49 79 135  2.12  0.347 
LAC  6 26 45 77  7 49 79 135  0.63  0.729 
β₂GPI  5 30 61 96  7 49 79 135  0.65  0.722 
ALL 3  1 6 18 25  7 49 79 135  1.62  0.445 
ANY  14 57 85 156   7 49 79 135   1.65   0.438 
               
 ANTIBODY POSITIVE  ANTIBODY NEGATIVE   
 ALLELE FREQUENCY  ALLELE FREQUENCY   
ANTIBODY  A C  A C  Z  p 
aCL  0.286 0.714  0.233 0.767  1.19  0.235 
LAC  0.247 0.753  0.233 0.767  0.32  0.746 
β₂GPI  0.208 0.792  0.233 0.767  -0.64  0.521 
ALL 3  0.16 0.84  0.233 0.767  -1.26  0.207 
ANY   0.272 0.728   0.233 0.767   1.08   0.279 
 
 
 
Table 39. Distribution of the -700 Polymorphism in antibody positive and antibody negative groups in white 
healthy controls. 
 ANTIBODY POSITIVE  ANTIBODY NEGATIVE   
 GENOTYPE    GENOTYPE     
ANTIBODY  AA CA CC Total  AA CA CC Total  χ2  p 
aCL  4 38 72 114  10 64 101 175  1.24  0.538 
LAC  2 28 24 54  10 64 101 175  4.05  0.132 
β₂GPI  2 22 48 72  10 64 101 175  2.11  0.348 
ALL 3  0 2 5 7  10 64 101 175  0.74  0.692 
ANY  8 71 112 191   10 64 101 175   0.45   0.797 
               
 ANTIBODY POSITIVE  ANTIBODY NEGATIVE   
 ALLELE FREQUENCY  ALLELE FREQUENCY   
ANTIBODY  A C  A C  Z  p 
aCL  0.202 0.798  0.24 0.76  -1.08  0.278 
LAC  0.296 0.704  0.24 0.76  1.13  0.258 
β₂GPI  0.181 0.819  0.24 0.76  -1.50  0.134 
ALL 3  0.143 0.857  0.24 0.76  -1.01  0.314 
ANY   0.228 0.772   0.24 0.76   -0.38   0.702 
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Table 40. Distribution of the -643 Polymorphism in antibody positive and antibody negative groups in all 
white samples. 
 ANTIBODY POSITIVE  ANTIBODY NEGATIVE   
 GENOTYPE    GENOTYPE     
ANTIBODY  CC TC TT Total  CC TC TT Total  χ2  p 
aCL  7 44 146 197  6 77 231 314  1.53  0.465 
LAC  2 37 95 134  6 77 231 314  0.54  0.765 
β₂GPI  8 44 118 170  6 77 231 314  3.32  0.190 
ALL 3  2 6 24 32  6 77 231 314  2.78  0.250 
ANY  11 90 256 357   6 77 231 314   1.01   0.602 
               
 ANTIBODY POSITIVE  ANTIBODY NEGATIVE   
 ALLELE FREQUENCY  ALLELE FREQUENCY   
ANTIBODY  C T  C T  Z  p 
aCL  0.147 0.853  0.142 0.858  0.22  0.825 
LAC  0.153 0.847  0.142 0.858  0.42  0.673 
β₂GPI  0.176 0.824  0.142 0.858  1.36  0.172 
ALL 3  0.156 0.844  0.142 0.858  0.30  0.768 
ANY   0.157 0.843   0.142 0.858   0.77   0.441 
 
 
 
Table 41. Distribution of the -643 Polymorphism in antibody positive and antibody negative groups in white 
SLE cases. 
 ANTIBODY POSITIVE  ANTIBODY NEGATIVE   
 GENOTYPE    GENOTYPE     
ANTIBODY  CC TC TT Total  CC TC TT Total  χ2  p 
aCL  3 17 58 78  3 36 98 137  0.95  0.622 
LAC  2 24 53 79  3 36 98 137  0.47  0.790 
β₂GPI  4 28 65 97  3 36 98 137  1.02  0.602 
ALL 3  2 3 20 25  3 36 98 137  4.31  0.116 
ANY  4 44 112 160   3 36 98 137   0.10   0.953 
               
 ANTIBODY POSITIVE  ANTIBODY NEGATIVE   
 ALLELE FREQUENCY  ALLELE FREQUENCY   
ANTIBODY  C T  C T  Z  p 
aCL  0.147 0.853  0.153 0.847  -0.17  0.867 
LAC  0.177 0.823  0.153 0.847  0.64  0.520 
β₂GPI  0.186 0.814  0.153 0.847  0.93  0.351 
ALL 3  0.14 0.86  0.153 0.847  -0.24  0.809 
ANY   0.163 0.838   0.153 0.847   0.30   0.764 
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Table 42. Distribution of the -643 Polymorphism in antibody positive and antibody negative groups in white 
healthy controls. 
 ANTIBODY POSITIVE  ANTIBODY NEGATIVE   
 GENOTYPE    GENOTYPE     
ANTIBODY  CC TC TT Total  CC TC TT Total  χ2  p 
aCL  4 27 88 119  3 41 133 177  0.86  0.652 
LAC  0 13 42 55  3 41 133 177  0.94  0.624 
β₂GPI  4 16 53 73  3 41 133 177  2.72  0.256 
ALL 3  0 3 4 7  3 41 133 177  1.50  0.471 
ANY  7 46 144 197   3 41 133 177   1.26   0.533 
               
 ANTIBODY POSITIVE  ANTIBODY NEGATIVE   
 ALLELE FREQUENCY  ALLELE FREQUENCY   
ANTIBODY  C T  C T  Z  p 
aCL  0.147 0.853  0.133 0.867  0.48  0.632 
LAC  0.118 0.882  0.133 0.867  -0.42  0.674 
β₂GPI  0.164 0.836  0.133 0.867  0.87  0.383 
ALL 3  0.214 0.786  0.133 0.867  0.73  0.466 
ANY   0.152 0.848   0.133 0.867   0.74   0.457 
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2. DISCUSSION 
 
Cardiovascular disease (CVD) is a leading cause of death in the United States, accounting for 
about 500,000-700,000 deaths each year.  It is a significant worldwide public health problem, 
causing about 12 million deaths per year.  In the US there are approximately 1.5 million cases of 
myocardial infarction (MI) each year (Garas et al. 2004).  People with SLE are at an increased 
risk for CVD.  Women with SLE between the ages of 35 to 44 have a 50-fold increased risk of 
MI.  While traditional risk factors, such as diabetes and hypertension, are important in CVD risk 
in SLE patients, they are insufficient to account for the amount of increased risk seen in SLE 
(Al-Herz et al. 2003).  CVD and SLE are both complex, multifactorial diseases caused by both 
environmental factors and genetics factors.  Several candidate genes have been identified as 
playing a possible role in CVD.  Because people suffering from SLE have a greater risk of CVD, 
it is possible that the genetic factors playing a role in CVD may also play a role in SLE or be 
present at a greater frequency in SLE populations. 
 
β2-GPI is one protein that is known to play a role in lipid metabolism and thought to play a role 
in atherosclerosis and aspects of SLE.  Thus, characterization of the affects of the APOH gene is 
important in piecing together the causes for CVD and SLE.  This study provides information 
about the associations of SNPs in the promoter region of the APOH gene with SLE, plasma β2-
GPI levels, and antiphospholipid antibodies. 
   
52 
 2.1. Distribution of the APOH promoter polymorphisms in Blacks and Whites 
 
Each promoter SNP was analyzed to determine its distribution in black and white subjects.  The -
1284 SNP had a very small minor allele frequency (0.006 in blacks, 0.002 in whites); therefore 
there was no difference seen between the races.  The presence of the G allele in this SNP was 
previously reported only in whites in a small sample 24 white and 23 black individuals 
sequenced (http://pga/gs.washington.edu/data/apoh/).  The present study found one black 
individual out of 82 genotyped for this SNP who was CG.  This subject may have some white 
ancestry or this could be evidence that the G allele does exist in the black population at a very 
low frequency.  
 
 There was a significant difference in the allele frequency of the -1219 SNP between blacks and 
white (p = 0.042).  The minor allele (A) was almost twice as common in the whites (0.096) as in 
blacks (0.056).  The allele frequencies reported by the University of Washington group for this 
SNP also showed that the frequency was twice as great in whites as in blacks; however, the 
frequencies were lower (whites- 0.04, blacks-0.02) than reported in this study. There was no 
significant difference seen in the genotype distribution or allele frequencies of the -1190 SNP 
between blacks and whites (p = .801).   
 
The -759 SNP differed in both genotype distribution (p = 0.002) and allele frequency (p <0.001) 
between black subjects and white subjects.  Similarly, the genotype distribution (p = 0.001) and 
allele frequencies (p <0.001) significantly differed between races for the -700 SNP.  The 
differences seen in the allele frequencies for the -759 and -700 SNPs are similar to the allele 
frequencies reported by the University of Washington group.   
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 That group found no difference in allele frequency in the -643 SNP between whites and blacks; 
however, the present study did detect a significant allele frequency difference of 0.091 in blacks 
and 0.149 in whites (p = 0.017).  The differences may be due to the small sample size of black 
subjects analyzed in both their sequencing efforts and the present study.  Because there are 
significant differences in the distributions of many of the APOH promoter SNPs between blacks 
and whites, further analysis was done in the races separately 
 
2.2. Association of the APOH promoter polymorphisms with SLE 
 
Association of each SNP with SLE was first analyzed individually in whites and blacks.  In the 
white subjects, the -1219 SNP was the only one to show a borderline significant association in 
allele frequencies (p = 0.089).  The frequency of the AA+AG genotypes was lower in SLE cases 
than in controls compared to the GG genotype (p = 0.057).  This association needs to be explored 
further to determine the significance of this difference.  Because the significance levels of the 
results in this study are borderline, further testing would be useful in determining whether this 
SNP actually influences the risk of SLE.  
 
In the African American samples, the -759 SNP (p = 0.022) and the -700 SNP (p = 0.035)  
showed significant differences in genotype distributions between cases and controls.  For the -
759 SNP, the frequency of the G allele was higher in cases then controls, but the difference was 
not statistically significant (0.175 vs. 0.077, p = 0.06).  The same trend was observed for the -700 
SNP, where the genotype difference was statistically significant between cases and controls (p = 
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 0.035) but not the allele frequency (p = 0.098).  This is possibly due to the small number of black 
cases and black controls.     
 
Since SNPs in a gene are often in linkage disequilibrium (LD) with each other, the extent of LD 
in the promoter of APOH was tested.  Several pairs of SNPs were in significant linkage 
disequilibrium with one another, and while none of the SNPs were in complete disequalibrium, 
several pairs showed high levels of didequalibrium (D’ >.90) (See Tables 10 and 11).  For these 
reasons, it is useful to determine the haplotype frequencies in this population and look for 
associations of the haplotypes with SLE.   
 
The T5 test statistic, which was used to determine if the haplotype pattern of 6 APOH SNPs, was 
significantly different between cases and controls.  The overall distribution of the haplotypes 
between cases and controls was significantly different (p = .00015).  This indicates that the 
haplotype analysis is more informative than individual SNP analysis.  However, the 4 most 
common haplotypes were not associated with SLE.  Individually, there were 8 haplotypes that 
differed significantly in frequency between cases and controls.  One of these haplotypes is 
relatively common, (6.1% in the total white sample) and its frequency was higher in controls 
than in cases (8.17 % vs. 3.2%, p < 0.001).  This suggests that this haplotype may have a 
protective effect against the risk of SLE.  One other haplotype also seems to have a protective 
effect; it was present in 1% of controls but was absent in cases (p = 0.006).  Conversely, 6 of 
these 8 haplotypes seem to be associated with SLE and may confer greater risk.  They are seen 
significantly more frequently in cases than in controls.  The most frequent risk haplotype was 
seen in 3.4% of SLE cases and 0.1% of controls (p <.001). 
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2.3. Association of the APOH promoter polymorphisms with plasma β2GPI levels 
 
Previous studies have shown that specific APOH coding polymorphisms affect plasma β2GPI 
levels (Kamboh et al. 1999).  Significant gene dosage effects were seen for codon 306 (p < 
.0001) and codon 316 (p <.0001).  β2GPI concentrations decreased linearly with increasing 
number of copies of the variant alleles for each codon.  It was found that codon 306 accounted 
for 30% of the variation in β2GPI levels and codon 316 accounted for 13% of the β2GPI plasma 
level variation (Kamboh et al. 1999).   
 
Whether or not the 6 APOH promoter polymorphisms in the present study affect plasma β2GPI 
levels has not previously been studied.  In the present project, the impact of 6 of the APOH 
promoter SNPs on plasma β2GPI levels was examined.  Only one of the 6 promoter 
polymorphisms analyzed in this study was associated with β2GPI levels.  The -643 SNP was 
mildly associated with the plasma levels of β2GPI in both white SLE cases (p = .096) and black 
controls (p = .081).  The trend seen overall in all groups for the -643 SNP was a gene-dosage 
effect, CC homozygotes had the highest β2GPI levels and TT homozygotes had the lowest β2GPI 
levels, with the heterozygotes falling in between.  This data indicated that the presence of the T 
allele may cause functional problems for the promoter.  Perhaps that SNP is in a critical area for 
promoter function, such as a binding site for a transcription factor or an enhancer element.  The 
statistical significance of this correlation is weak; therefore, more subjects should be analyzed to 
see if this effect persists with a larger sample size.  Functional analysis of the promoter would be 
useful in supporting this data.         
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2.4. Association of the APOH promoter polymorphisms with antiphospholipid antibodies 
 
Previous research has been done to analyze whether or not genetic variation in the coding region 
of the APOH gene is associated with the presence of antiphospholipid antibodies (APA).  One 
polymorphism was reported to be associated with the presence of APA.  The allele frequencies 
and the distribution of the genotypes for the codon 316 polymorphism differed between APA-
positive subjects and APA-negative subjects (Kamboh et al. 1999). No research has been done as 
to the association of APOH promoter SNPs with APA. 
 
In order to investigate whether or not the APOH promoter polymorphisms are markers for the 
presence of APA, the genotype and allele distributions were analyzed for each SNP between 
subjects negative for all APA and 4 groups of antibody positive people: positive for aCL, 
positive for LAC, positive for anti- β2GPI, positive for any antibody, and positive for all three 
antibodies.  This analysis was only done in whites due to the small sample size of the black 
subjects. 
 
The only differences found were between the APA negative group and the group positive for all 
three antibodies.  The differences seen were present in both the total white sample and the white 
SLE cases, but not in the white controls.  This is because there were only 7 control samples that 
were positive for all 3 antibodies.  Therefore the differences seen in the overall population for the 
all antibody positive group are reflective of the differences seen in the SLE cases, thus further 
discussion of the all antibody positive group will focus on the SLE cases only. 
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For the -1284 SNP, genotype distribution was significantly different between the all positive and 
the negative antibody groups (p = 0.02).  None of the 139 antibody negative SLE cases  
genotyped for the -1284 SNP were of the CG genotype, while 1 out of the 25 cases in the all 
antibody positive group was CG.  This difference is statistically significant; however, the minor 
allele frequency is so low that it is not unusual to only see the G allele in 1 out of 166 subjects. 
 
The allele frequencies for the -759 SNP and for the -700 SNP differed significantly between the 
all positive and the negative antibody group (p = 0.046, p = 0.095).  The minor allele was seen 
more frequently in the antibody negative group for both SNPs.  This indicates that the presence 
of the minor allele at these polymorphic sites may be associated with protection against 
production if APA.  However, this difference was not noted for any of the antibodies 
individually or for the group of subjects positive for at least one antibody.  The group of people 
positive for all three antibodies is small, thus it would be beneficial to replicate these results with 
a larger sample size. 
 
2.5. Summary 
 
This study has examined 6 SNPs within the promoter region of the APOH gene.  Differences 
between blacks and whites were analyzed, as well as associations with SLE, plasma β2GPI 
levels, and antiphospholipid antibodies.  Significant findings from this study are as follows: 
 
1) The distribution of 4 of the 6 SNPs was significantly different between blacks and whites.   
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 2) The genotype distribution of the -1219 SNP showed a marginally significant association 
with SLE in whites (p= 0.057).  On the other hand, the genotype distributions of the -759 
SNP and the -700 SNP significantly differed between SLE cases and controls in blacks  
(p = 0.022, p = 0.035). 
3) The haplotype pattern in the white sample was significantly associated with SLE risk (p = 
0.00015).   
4) The -643 SNP has a moderate affect on plasma β2-GPI levels in white SLE cases (p = 
0.096) and black controls (p = 0.081). 
5) Significant differences were seen in the distribution of the -1284 SNP between the 
antibody negative group and the antibody group positive for all three antibodies in whites 
overall (p = 0.05) and in cases (p = 0.02) 
6) Significant differences were seen in the allele frequency of the -759 SNP between the all 
3 antibody positive group and the antibody negative group in whites overall (p = 0.03) 
and in cases (p = 0.046). 
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